open access

Vol 13, No 1 (2010)
Published online: 2010-12-01
Submitted: 2012-01-23
Get Citation

The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid

Ramin Sadeghi, Seyed Rasoul Zakavi, Mohammad Naser Forghani, Kamran Aryana, Vahid Reza Dabbagh Kakhki, Narjes Khatoon Ayati, Fatemeh Homaee Shandiz, Mohammad Reza Ghavamnasiri, Mohammed Keshtgar
Nucl. Med. Rev 2010;13(1):1-4.

open access

Vol 13, No 1 (2010)
Published online: 2010-12-01
Submitted: 2012-01-23

Abstract

BACKGROUND: To study the value of periareolar intra-dermal injection of Tc-99m sestamibi (MIBI) for sentinel node mapping in breast carcinoma.
MATERIAL AND METHODS: Fifty patients with early-stage breast cancer were included in our study. 17.5 MBq Tc-99m-MIBI was injected intradermally to 25 patients and the remainders were injected with the same dose of Tc-99m-antimony sulphide colloid. Anterior and lateral static images were taken at 2 minutes. If sentinel lymph node was not detected, delayed imaging by up to 180 minutes was carried out. The patients were operated on 2–4 hours post-injection. Sentinel lymph node biopsy was performed by the aid of gamma probe and blue dye during surgery.
RESULTS: In the Tc-99m-MIBI group, 23 patients had lymph nodes on scintigraphy images, and sentinel nodes were detected during surgery in all 23 patients. In the Tc-99m-antimony sulphide colloid group, 24 patients had lymph nodes on scintigraphy images, and sentinel nodes were identified during surgery in 24 patients.
CONCLUSIONS: We concluded that 99mTc-MIBI is a suitable radiopharmaceutical for sentinel node detection.

Nuclear Med Rev 2010; 13, 1: 1–4

Abstract

BACKGROUND: To study the value of periareolar intra-dermal injection of Tc-99m sestamibi (MIBI) for sentinel node mapping in breast carcinoma.
MATERIAL AND METHODS: Fifty patients with early-stage breast cancer were included in our study. 17.5 MBq Tc-99m-MIBI was injected intradermally to 25 patients and the remainders were injected with the same dose of Tc-99m-antimony sulphide colloid. Anterior and lateral static images were taken at 2 minutes. If sentinel lymph node was not detected, delayed imaging by up to 180 minutes was carried out. The patients were operated on 2–4 hours post-injection. Sentinel lymph node biopsy was performed by the aid of gamma probe and blue dye during surgery.
RESULTS: In the Tc-99m-MIBI group, 23 patients had lymph nodes on scintigraphy images, and sentinel nodes were detected during surgery in all 23 patients. In the Tc-99m-antimony sulphide colloid group, 24 patients had lymph nodes on scintigraphy images, and sentinel nodes were identified during surgery in 24 patients.
CONCLUSIONS: We concluded that 99mTc-MIBI is a suitable radiopharmaceutical for sentinel node detection.

Nuclear Med Rev 2010; 13, 1: 1–4

Get Citation

Keywords

breast cancer; lymphoscintigraphy; sentinel lymph node; Tc-99m-MIBI; Tc-99m-antimony sulphide colloid; intradermal injection

About this article
Title

The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid

Journal

Nuclear Medicine Review

Issue

Vol 13, No 1 (2010)

Pages

1-4

Published online

2010-12-01

Bibliographic record

Nucl. Med. Rev 2010;13(1):1-4.

Keywords

breast cancer
lymphoscintigraphy
sentinel lymph node
Tc-99m-MIBI
Tc-99m-antimony sulphide colloid
intradermal injection

Authors

Ramin Sadeghi
Seyed Rasoul Zakavi
Mohammad Naser Forghani
Kamran Aryana
Vahid Reza Dabbagh Kakhki
Narjes Khatoon Ayati
Fatemeh Homaee Shandiz
Mohammad Reza Ghavamnasiri
Mohammed Keshtgar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl